1 – 5 of 42
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology
(
- Contribution to journal › Article
- 2023
-
Mark
Digital lifestyle treatment improves long-term metabolic control in type 2 diabetes with different effects in pathophysiological and genetic subgroups
(
- Contribution to journal › Article
- 2022
-
Mark
The role of circulating galectin-1 in type 2 diabetes and chronic kidney disease : evidence from cross-sectional, longitudinal and Mendelian randomisation analyses
(
- Contribution to journal › Article
-
Mark
Effect of self-managed lifestyle treatment on glycemic control in patients with type 2 diabetes
(
- Contribution to journal › Article
- 2018
-
Mark
Novel diabetes subgroups – Authors' reply
(
- Contribution to journal › Letter